Cargando…
Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that ab...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784389/ https://www.ncbi.nlm.nih.gov/pubmed/35083147 http://dx.doi.org/10.3389/fonc.2021.789330 |
_version_ | 1784638726494748672 |
---|---|
author | Yang, Zhengyang Deng, Wei Zhang, Xiao An, Yongbo Liu, Yishan Yao, Hongwei Zhang, Zhongtao |
author_facet | Yang, Zhengyang Deng, Wei Zhang, Xiao An, Yongbo Liu, Yishan Yao, Hongwei Zhang, Zhongtao |
author_sort | Yang, Zhengyang |
collection | PubMed |
description | Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, nanotechnology-based anti-angiogenic therapies have emerged as a new way to treat digestive tumours. Compared with commonly used drugs, nanoparticles show great potential in tumour targeted delivery, controlled drug release, prolonged cycle time, and increased drug bioavailability. Therefore, anti-angiogenic nanoparticles may be an effective complementary therapy to treat digestive tumours. In this review, we outline the different mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in various kinds of digestive tumours. In addition, the opportunities and challenges are briefly discussed. |
format | Online Article Text |
id | pubmed-8784389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87843892022-01-25 Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies Yang, Zhengyang Deng, Wei Zhang, Xiao An, Yongbo Liu, Yishan Yao, Hongwei Zhang, Zhongtao Front Oncol Oncology Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, nanotechnology-based anti-angiogenic therapies have emerged as a new way to treat digestive tumours. Compared with commonly used drugs, nanoparticles show great potential in tumour targeted delivery, controlled drug release, prolonged cycle time, and increased drug bioavailability. Therefore, anti-angiogenic nanoparticles may be an effective complementary therapy to treat digestive tumours. In this review, we outline the different mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in various kinds of digestive tumours. In addition, the opportunities and challenges are briefly discussed. Frontiers Media S.A. 2022-01-10 /pmc/articles/PMC8784389/ /pubmed/35083147 http://dx.doi.org/10.3389/fonc.2021.789330 Text en Copyright © 2022 Yang, Deng, Zhang, An, Liu, Yao and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Zhengyang Deng, Wei Zhang, Xiao An, Yongbo Liu, Yishan Yao, Hongwei Zhang, Zhongtao Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies |
title | Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies |
title_full | Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies |
title_fullStr | Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies |
title_full_unstemmed | Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies |
title_short | Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies |
title_sort | opportunities and challenges of nanoparticles in digestive tumours as anti-angiogenic therapies |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784389/ https://www.ncbi.nlm.nih.gov/pubmed/35083147 http://dx.doi.org/10.3389/fonc.2021.789330 |
work_keys_str_mv | AT yangzhengyang opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies AT dengwei opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies AT zhangxiao opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies AT anyongbo opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies AT liuyishan opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies AT yaohongwei opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies AT zhangzhongtao opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies |